CV Therapeutics kept by Merrill at buy

CV Therapeutics Inc. was maintained by Merrill Lynch analyst Ben Li at a buy rating with a stock price target of $33 per share following the company filing an amendment Wednesday to the New Drug Application for its angina drug Ranexa. Merrill noted the filing was about a month earlier than expected. CV Therapeutics shares Thursday rose $0.59, or 2.12%, to close at $28.41 on volume of 778,338 shares versus the three-month running average of 932,797 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.